573,167 Shares in Lantheus Holdings, Inc. $LNTH Purchased by Nuveen LLC

Key Points

• Nuveen LLC acquired 573,167 shares of Lantheus Holdings, Inc. for approximately $55.9 million, representing about 0.84% of the company's stock as of their latest SEC filing.
• The company reported $1.57 earnings per share for the last quarter, missing the consensus estimate of $1.65, with a year-over-year revenue decline of 4.1%.
• Current analyst ratings suggest a consensus of "Moderate Buy" for Lantheus Holdings, with an average price target of $105.50.

Nuveen LLC bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 573,167 shares of the medical equipment provider's stock, valued at approximately $55,941,000. Nuveen LLC owned 0.84% of Lantheus at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the stock. Signaturefd LLC grew its position in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 116 shares in the last quarter. Hughes Financial Services LLC acquired a new stake in Lantheus in the first quarter valued at approximately $81,000. UMB Bank n.a. grew its position in Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after acquiring an additional 381 shares in the last quarter. Blue Trust Inc. grew its position in Lantheus by 117.7% in the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after acquiring an additional 633 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock valued at $128,000 after buying an additional 298 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on LNTH shares. Mizuho reduced their target price on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. JMP Securities reduced their target price on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. B. Riley reduced their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $105.50.

Lantheus Stock Performance

NASDAQ LNTH traded down $0.79 during trading hours on Tuesday, hitting $55.18. The company had a trading volume of 174,082 shares, compared to its average volume of 1,157,540. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $118.21. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The business has a fifty day simple moving average of $73.29 and a 200-day simple moving average of $85.13. The firm has a market cap of $3.75 billion, a P/E ratio of 14.68 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). The company had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.Lantheus's quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the prior year, the business earned $1.80 earnings per share. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.